UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Lexaria Bioscience Corp.

(Name of Issuer)

Common Stock, Par Value $0.001

(Title of Class of Securities)


52886N
(CUSIP Number)

Robert B. Goldberg, Esq.
5555 Glenridge Connector, Suite 675
Atlanta, Georgia 30342
(404)233-2800
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

December 31, 2023
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a Statement
on Schedule 13G to report the acquisition that is the
subject of this Schedule 13D and is filing this schedule
because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box [      ].

Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits.
See Rule 13d-7 for other parties to whom copies are to be sent.


* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures
provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP NO. 52886N
Cover Page

1

NAMES OF REPORTING PERSONS

Wayne W. Boos

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)
(a) [   ]
(b) [   ]

3

SEC USE ONLY

4

SOURCE OF FUNDS (See Instructions)

PF

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e).  [   ]

6

CITIZENSHIP OR PLACE OF ORGANIZATION

U.S.A.

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH:

7

SOLE VOTING POWER

480,000

8

SHARED VOTING POWER

9

SOLE DISPOSITIVE POWER

480,000

10

SHARED DISPOSITIVE POWER

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

480,000

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions)
[   ]

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

4.67078%1

14

TYPE OF REPORTING PERSON (See Instructions)

      IN

SCHEDULE 13D

This Amendment No. 1 relates to the Schedule 13D
filed with the Securities and Exchange Commission on
September 18, 2023, relating to the the Common Stock,
Par Value $0.001 (the Common Stock) of Lexaria Bioscience Corp.,
a Nevada corporation (the Company).  The principal executive
offices of the Company are located at #100, 740 McCurdy Road,
Kelowna, BC, Canada VIX 2P7.

Item 5 of the Schedule is hereby amended and supplemented as follows:

Item 5.	Interest in Securities of the Issuer.

(a) As of December 31, 2023, Wayne W. Boos beneficially owns
a total of 480,000 shares of the Companys Common Stock which
represent approximately 4.67078% of the outstanding Common Stock,
based on 10,276,641 Common Stock outstanding as of November 20, 2023,
as indicated by the Company. The percentage of Mr. Boos ownership of
Common Stock in the Company has varied since the filing of this
Schedule 13D as Mr. Boos has (i) purchased additional shares of the
Companys Common Stock, (ii) he has sold shares of the Companys
Common Stock, and (iii) the Company has issued additional shares of
Common Stock.

(b) Nature of Ownership.  Wayne W. Boos has the sole power to
vote and direct the disposition of all of the 480,000 shares
reported as beneficially owned by him.

(c) Recent Transactions.  In the 60 days prior to
December 31, 2023, Wayne W. Boos (i) sold 30,000 shares of the
Companys Common Stock for an average price per share of $1.31
and (ii) acquired 90,000 shares of the Companys Common Stock
for an average price per share of $1.405597 through his broker,
Merrill Lynch.

(d)No other person has the right to receive or the power to
direct the receipt of the dividends from, or proceeds from the
sale of, such securities.

(e) Wayne W. Boos ceased to be the beneficial owner of more than
five percent of the Companys Common Stock on or about
October 3, 2023, when the Company issued additional
shares of the Companys Common Stock.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.

Date: February 14, 2024
/s/ Wayne W. Boos
Wayne W. Boos

1 Based on the 10,276,641 shares of Common Stock
outstanding as of November 20, 2023.